HY 091
Alternative Names: HY-091Latest Information Update: 02 Feb 2024
At a glance
- Originator AFT Pharmaceuticals; Hyloris Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Vulvar lichen sclerosus
Most Recent Events
- 18 Jan 2024 AFT Pharmaceuticals and Hyloris Pharmaceuticals agree to co-develop HY 091 for Vulvar Lichen Sclerosus
- 18 Jan 2024 Early research in Vulvar lichen sclerosus in Belgium (unspecified route), prior to January 2024
- 18 Jan 2024 Early research in Vulvar lichen sclerosus in New Zealand (unspecified route), prior to January 2024